Skip Navigation

ALS Research

The Emory ALS Center is actively engaged in research ranging from basic questions about the causes of ALS to clinical trials of new drugs in people with ALS.  Please read below to learn more about our research program and projects.  We need your help and participation in the fight against ALS.

In our laboratories: Dr. Glass' laboratory in the Center for Neurodegenerative Disease is working on the basic mechanisms of motor neuron disease as well as potential new treatments for ALS.  Your contributions, whether monetary or participation in one of our studies, are essential for our continued productivity.  Thank you!

Glass2016

Dr. Glass is working on several projects and has been actively collaborating with other ALS investigators around the world on issues of ALS genetics, immunology, neuropathology, and animal and cellular models of ALS.  There are several ongoing and planned clinical trials outlined below.  Dr. Glass also continues his work on discovering “biomarkers” of ALS, which requires the participation of PALS and CALS.  We are collecting blood and spinal fluid samples from patients for our research.  Family members and non-related adults are also important participants in our studies, since we need to compare our results between those with and without ALS. Link to publications by Dr. Glass HERE.  

 

Fournier2016

 Dr. Christina Fournier was recently awarded a 5-year research grant from the Veterans Administration.  Her project is to develop a new questionnaire to measure the progression of ALS.  The questions will be related to function, similar to the current ALS Functional Rating Scale (ALSFRS) that is performed at each clinic visit.  The hope is that Dr. Fournier’s new scale will be more sensitive to changes in function in PALS, making it useful both for clinical care and for research trials. Please agree to participate in this important effort by filling out the questionnaires if you are asked. Link to publications by Dr. Fournier HERE.

 

We at the Emory ALS Center understand the dire need for effective treatments for ALS.  The problems we face in developing new therapies for ALS will only be solved by rigorous scientific investigation, which takes team efforts of clinicians and scientists around the world, adequate research funding, and of course time.  Most importantly, we need to partner with our patients and their families to study and better understand YOUR disease!  Your participation in research is essential!

Watch our website for upcoming clinical research and trials.  In order to understand ALS better, why it happens and what is important for progression, we need YOUR participation in research studies and clinical trials.

clinical trials (treatment with an experimental drug)

Acthar: ENROLLING--This phase 2 placebo-controlled trial sponsored by Mallinckrodt will test the safety, tolerability, and pharmacokinetics of an investigational injectable drug in patients with ALS. Click here for complete information. Contact Janet Brantley at 404-727-1673  or janet.m.brantley@emory.edu .

Centaur: ENROLLING-- Amylyx Pharmaceuticals is offering a phase II trial investigating the safety and tolerability of a new combination of drugs (already FDA approved for other diseases) in ALS.  Click here for complete information. Contact Janet Brantley at 404-727-1673 or janet.m.brantley@emory.edu .

Single and Multiple Dose Study of BIIB067: ENROLLING--This is a Phase 1 placebo-controlled study from Biogen. Click here for eligibility and information. Contact Anna Partlow at 404-778-3181 or apartlo@emory.edu.

FORTITUDE Study: ENROLLING —Cytokinetics is sponsoring a study to assess safety and tolerability of CK-2127107 in patients with ALS. Click here for complete information. Contact Meraida Polak, RN at 404-778-3807 or mpolak@emory.edu.

Genentech GDC-0134:  ENROLLING--This is a first-in-human study to examine whether the drug GDC-0134 is safe and tolerable in people with ALS. Click here for complete study information. Contact Jane Bordeau, RN at 404-727-1679 or jrbord@emory.edu .

OrionPharma Trial of Levosimendan in ALS (RefALS): ENROLLING SOON-- OrionPharma is sponsoring a Phase 3 study of the drug levosimendan in people with ALS. Levosimendan is an FDA-approved medication for heart failure that acts by causing the heart muscle to beat more strongly. Click here for more information. Contact Jane Bordeau at jrbord@emory.edu.

HAVE YOU ENROLLED IN THE NATIONAL ALS REGISTRY??

registry 

www.alsa.org/als-care/als-registry  

Done